Skip to Main Content
Contribute Try STAT+ Today

After decades of attempts to develop treatments for Alzheimer’s disease, scientists still have precious little to show for it. Now, after some high-profile failures, there are big questions about where researchers can turn next.

Join STAT senior science writer Sharon Begley and STAT senior medicine writer Matt Herper for a subscriber-only live chat on Alzheimer’s research, the beta-amyloid theory, and the effort to develop new therapies. They’ll also be discussing the latest news out of the Alzheimer’s Association International Conference.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.